New hope for Tough-to-Treat blood cancer
NCT ID NCT07168317
Summary
This study is testing a new combination of immunotherapy, chemotherapy, and other drugs for people newly diagnosed with a rare and aggressive type of lymphoma called AITL. The goal is to see if this combination is more effective and safer than current treatments, which often don't work well and have high relapse rates. Researchers will measure how well the treatment works and monitor side effects in about 40 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEW DIAGNOSED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.